Davis Selected Advisers reduced its stake in shares of Humana Inc. (NYSE:HUM – Free Report) by 2.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,256,909 shares of the insurance provider’s stock after selling 52,648 shares during the quarter. Humana makes up 3.3% of Davis Selected Advisers’ holdings, making the stock its 11th largest position. Davis Selected Advisers owned 1.87% of Humana worth $572,600,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently modified their holdings of HUM. FPC Investment Advisory Inc. purchased a new position in shares of Humana in the fourth quarter worth $27,000. Centricity Wealth Management LLC purchased a new stake in Humana during the 4th quarter valued at about $30,000. Ashton Thomas Securities LLC purchased a new stake in Humana during the 3rd quarter valued at about $31,000. Atwood & Palmer Inc. grew its stake in Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after purchasing an additional 60 shares during the last quarter. Finally, Kestra Investment Management LLC purchased a new stake in Humana during the 4th quarter valued at about $49,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.
Humana Stock Down 2.2 %
Shares of HUM opened at $259.86 on Friday. The firm’s 50 day moving average is $271.80 and its 200-day moving average is $284.13. The stock has a market capitalization of $31.35 billion, a PE ratio of 26.12, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46.
Humana Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.36%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio (DPR) is currently 35.58%.
Analyst Ratings Changes
HUM has been the topic of several recent research reports. StockNews.com lowered shares of Humana from a “buy” rating to a “hold” rating in a report on Wednesday. Piper Sandler upped their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Barclays lifted their price objective on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Truist Financial upped their price objective on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Twenty investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Humana has a consensus rating of “Hold” and an average target price of $285.68.
Get Our Latest Stock Analysis on HUM
Insider Activity at Humana
In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.32% of the stock is currently owned by insiders.
Humana Profile
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Stories
- Five stocks we like better than Humana
- Using the MarketBeat Dividend Yield Calculator
- Is Myers Industries Poised for a Breakout?
- What is the S&P/TSX Index?
- Is BigBear.ai’s 25% Plunge a False Alarm or Fire Sale?
- 10 Best Airline Stocks to Buy
- Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.